Edwards Lifesciences (EW) Osake Kurssi

Edwards Lifesciences Corp is primarily active in the healthcare industry, specifically in the field of medical devices. The company specializes in the development and manufacturing of innovative heart valves, monitoring systems, and critical care technologies. With a strong focus on cardiovascular diseases, Edwards Lifesciences Corp offers solutions that improve patient outcomes and quality of life. Leveraging their expertise and cutting-edge technology, the company continues to make significant contributions to the medical industry, addressing the growing need for advanced cardiovascular treatments and therapies.

The main competitors of Edwards Lifesciences Corp in the market include Medtronic, Boston Scientific, and Abbott Laboratories. These companies also operate in the medical devices and equipment industry, offering various products and services related to cardiovascular healthcare. Edwards Lifesciences Corp, a leading player in this sector, faces intense competition from these firms in areas such as heart valve replacement, monitoring systems, and other innovative technologies. However, Edwards Lifesciences Corp has maintained a strong market presence and gained a competitive edge through its exceptional products, continuous advancements, and significant customer trust.

Edwards Lifesciences Corp is a medical technology company founded in 1958. It specializes in developing and manufacturing products for patients with cardiovascular disease. With its headquarters in Irvine, California, Edwards Lifesciences Corp has grown to become a leading global player in the healthcare industry. The company is renowned for its innovative heart valves and hemodynamic monitoring systems, which help improve the lives of patients suffering from heart conditions. Edwards Lifesciences Corp has a rich history of pioneering breakthroughs in heart surgery, making it a trusted name in the field of cardiac care.

Some significant milestones achieved by Edwards Lifesciences Corp include the introduction of the first commercially available artificial heart valve in 1960, the development of the first transcatheter aortic valve system known as SAPIEN in 2002, and the successful launch of the SAPIEN 3 Ultra system in 2015, which showcased improved patient outcomes. Edwards Lifesciences Corp has also achieved regulatory approvals and expanded its product portfolio, providing innovation in heart valve therapy. The company continues to make advancements in medical technology, contributing to improved patient care and enhancing its position in the medical device industry.

Edwards Lifesciences Corp is primarily present in various countries and regions worldwide. The company has a global presence, with a strong focus on North America, Europe, and the Asia-Pacific region. Their innovative medical technologies for cardiovascular disease management and critical care solutions are utilized by healthcare professionals in hospitals and medical centers across the United States, Canada, Germany, France, the United Kingdom, Japan, China, India, and many other countries. Edwards Lifesciences Corp's commitment to advancing patient care extends to various markets, ultimately benefiting individuals and healthcare systems globally.

Edwards Lifesciences Corp represents values of innovation, patient focus, and global collaboration. The company's corporate philosophy revolves around improving patient lives through its life-saving technologies and innovative medical solutions. Edwards Lifesciences Corp is committed to delivering high-quality, accessible, and cost-effective healthcare solutions worldwide. With a strong emphasis on research and development, the company aims to pioneer breakthrough technologies in heart valve therapies and critical care monitoring. Edwards Lifesciences Corp's dedication to improving patient outcomes, advancing medical science, and enhancing the quality of life sets it apart as a renowned leader in the healthcare industry.

Analyytikot asettavat tällä hetkellä Edwards Lifesciences-osakkeelle keskimääräisen tavoitehinnan 101,70 USD (mediaani: 101,00 USD), mikä merkitsee +10,5 % viimeisimpään hintaan verrattuna. Konsensus perustuu 38 analyytikkoarvioon.

Edwards Lifesciences Analyytikkojen kursstavoitteet 2026

38 analyytikkoa arvioi tällä hetkellä Edwards Lifesciences-osaketta: 31 suosittaa ostoa, 7 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Edwards Lifesciences-yhtiöltä 6,77 Mrd. USD liikevaihtoa ja 3,02 USD osakekohtaista tulosta.

Edwards Lifesciences Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Edwards Lifesciences-osake noteerataan hintaan 82,45 EUR (92,01 USD).

Edwards Lifesciences-osake (EW) on listattuna 9 pörssissä, muun muassa: NYSE (EW), London (0REN.L), SIX (Zürich) (EW.SW), XETRA (EWL.DE), Frankfurt (EWL.F), München (EWL.MU), Düsseldorf (EWL.DU), Wien (EWLS.VI).

Edward Lifesciences Corp is a multinational company that has been developing and producing innovative medical products for heart and vascular diseases for over 60 years. With headquarters in California, USA, the company operates worldwide and employs over 14,000 employees. Edward Lifesciences Corp is a market leader in heart valve and heart monitoring equipment. The company's business model focuses on three main areas: heart valves, hemodynamics, and critical care. In the field of heart valves, the company develops a wide range of products such as biological aortic valves, mechanical aortic valves, transcatheter aortic valve implants (TAVI), mitral valves, and pulmonary valves. These products are used to treat patients with a variety of heart diseases and are known for their high precision, safety, and effectiveness. In the field of hemodynamics, Edward Lifesciences Corp offers products such as catheters, sensors, and monitoring devices for hospitals and clinics. These products help doctors and medical staff to accurately monitor the hemodynamics of patients, especially in the intensive care unit, and to respond quickly and precisely. The critical care division of Edward Lifesciences Corp provides medical devices for monitoring and supporting patients in the intensive care unit. These products include ventilators, blood gas analyzers, and monitoring devices for vital signs. Edward Lifesciences Corp is globally recognized for its research and development and its commitment to the highest standards in medicine. In 1958, Miles "Lowell" Edwards, the founder of the company, invented the first artificial heart valve. Since then, Edward Lifesciences Corp has introduced a variety of innovative products to the market and continues to work on improving the lives of heart patients worldwide. The company is also known for its ability to incorporate the latest technologies into its products. For example, TAVI implants were developed based on the latest innovations in minimally invasive surgery. With the use of state-of-the-art technology and intensive research, the company has established itself as a leading provider of medical devices. Edward Lifesciences Corp is continuously working to improve its business model and incorporate new products and services into its portfolio. The company is not only a leader in research and development but also in the production, marketing, and distribution of its products. Edward Lifesciences Corp is committed to always offering innovative and effective solutions for patients with heart diseases in order to improve their quality of life.

odotettu liikevaihto Edwards Lifesciences on 6,77 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Edwards Lifesciences on 1,76 Mrd. USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Edwards Lifesciences:n hinta-voitto-suhde (P/E) on tällä hetkellä 30,48. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Edwards Lifesciences-osakkeen arvostusta.

Edwards Lifesciences:n hinta-myynti-suhde (P/S) on tällä hetkellä 7,91. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Edwards Lifesciences-osakkeen arvostuskennuslukuna.

Edwards Lifesciences:n Eulpool-laatuscore on 6/10.

Edwards Lifesciences:n ISIN on US28176E1082. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Edwards Lifesciences:n WKN on 936853. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Edwards Lifesciences:n ticker on EW. Tämä pörssinoteeraus käytetään Edwards Lifesciences-osakkeiden kauppaan pörssissä.